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Abstract
One of the major components in high-fat diets (Western diet) is the omega (ω, n)-6
polyunsaturated fatty acid (PUFA) called linoleic acid (LA). Linoleic acid is the precursor for
arachidonic acid (AA). These fatty acids are metabolized to an array of eicosanoids and
prostaglandins depending upon the enzymes in the pathway. Aberrant expression of the catabolic
enzymes such as cyclooxygenases (COX-1 and/or -2) or lipoxygenases (5-LO, 12-LO, 15-LO-1, and
15-LO-2) that convert PUFA either AA and/or LA to bioactive lipid metabolites appear to
significantly contribute to the development of PCa. However, PUFA and its cellular interactions in
PCa are poorly understood. We therefore examined the mRNA levels of key enzymes involved in
the LA and AA pathways in 18 human donor (normal) prostates compared to 60 prostate tumors
using the Affymetrix U95Av2 chips. This comparative (normal donor versus prostate cancer) study
showed that: 1) the level of 15-LO-1 expression (the key enzyme in the LA pathway) is low (P <
0.001), whereas the levels of delta-5 desaturase (P < 0.001, the key enzyme in the AA pathway),
delta-6 desaturase (P = 0.001), elongase (P = 0.16) and 15-lipoxygenase-2 (15-LO-2, P = 0.74) are
higher in donor (normal) prostates, and 2) Contrary to the observation in the normal tissues,
significantly high levels of only 15-LO-1; whereas low levels of delta-6 desaturase, elongase, delta-
5 desaturase and 15-LO-2 respectively, were observed in PCa tissues. Although the
cyclooxygenase (COX)-1 and COX-2 mRNA levels were high in PCa, no significant differences
were observed when compared in donor tissues. Our study underscores the importance of
promising dietary intervention agents such as the omega-3 fatty acids as substrate competitors of
LA/AA, aimed primarily at high 15-LO-1 and COX-2 as the molecular targets in PCa initiation and/
or progression.
Findings
Prostate cancer (PCa) remains the second most com-
monly diagnosed cancer in American men, with over
230,000 new cases predicted for 2005 alone [1]. Projec-
tions estimate that the number of new cases of PCa during
the next 20 years will more than double and the number
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of men dying of the disease could double or triple during
this same interval [2]. The incidence and mortality of PCa
vary greatly in different geographic regions of the world
[3,4]. Lifestyle factors, such as diet, likely contribute to
these differences since migrants from low- to high-risk
regions typically develop a higher PCa risk, often within
one generation. The typical U.S. diet-rich in vegetable oils,
animal fats and meats that contain heterocyclic aromatic
amine carcinogens [5-8] and poor in fruits and vegetables
that contain carcinogen-detoxification enzyme inducers
and antioxidants such as lycopene [6,9,10]-almost cer-
tainly plays a role in the high incidence of PCa found in
America. Examples of dietary fat that impact PCa include
n-3 and n-6 polyunsaturated fatty acids (PUFAs), both of
which play important roles in many normal human bio-
logical processes. As humans cannot synthesize sufficient
quantities of n-3 and n-6 PUFAs, they are considered
essential fatty acids. While all mammalian cells can inter-
convert the PUFAs within each series by elongation, desat-
uration and retro conversion, the two series are not
interchangeable due to the lack of the Fat-1 gene [11],
which encodes the n-3 desaturase enzyme [12,13]. Lino-
leic acid (LA; 18:2, n-6) represents an n-6 PUFA com-
monly found in high-fat Western diets [14]. Terrestrial
plants synthesize LA, and once ingested by mammals, LA
is either metabolized to 13-(S)-hydroxyoctadecadienoic
acid [13-(S)-HODE] or converted further to arachidonic
acid (AA; 20:4, n-6). Three fatty acids, found primarily in
fish oils, comprise the n-3 family: Alpha linolenic acid
(ALA or α-LNA; 18:3, n-3), eicosapentaenoic acid (EPA;
20:5, n-3), and docosahexaenoic acid (DHA; 22:6, n-3).
ALA, synthesized by cold-water vegetation, is converted to
EPA and DHA by fish. Of note, through the same series of
enzymes used to convert LA to AA, humans can synthesize
EPA from ingested ALA. EPA can then be converted to
DHA. We are left with tantalizing suggestions from epide-
miological investigations that consuming n-3 fatty acids
have many health benefits [15-20]. Complimentary Alter-
native Medicine (CAM) involving the use of natural and
dietary agents for cancer prevention may prove a valuable
strategy in the fight against PCa [21-33]. Due to the prob-
able impact of n-3 and n-6 PUFAs on PCa development,
delaying the PCa progression by n-3 PUFAs will provide
for tangible benefits in alleviating the adverse conse-
quences of PCa, which is approaching epidemic propor-
tions in the United States. Therefore it is imperative to
understand how the n-6 and n-3 pathways operate in
human prostate especially during prostate carcinogenesis.
We analyzed the mRNA expression levels of these
enzymes in normal and cancer prostate tissues from
humans to study the LA and AA pathways. The tumor and
normal donor tissue samples were acquired from the Uni-
versity of Pittsburgh Medical Center under stringent Insti-
tutional Review Board guidelines with appropriate
informed consent. Specimens were received directly from
the operating room. Samples (>500 mg) were excised and
snap frozen in liquid nitrogen within 30 min of excision
and stored at -80°C in the University of Pittsburgh Pathol-
ogy Tissue Bank until extraction of RNA. All samples were
submitted for pathology evaluation. In every case, the tis-
sue was excised from the junction between the ejaculatory
duct and the prostatic urethra in the peripheral zone of
the prostate and their histological diagnosis was con-
firmed microscopically. Donor tissue specimens were
received through a collaborative arrangement with the
Center for Organ Recovery and Education (CORE), the
local organ procurement agency. The arrangement allows
the University of Pittsburgh Pathology Tissue Bank to
acquire normal prostates and associated serum/plasma
specimens from healthy individuals who have donated
their organs for transplant. There is extensive collabora-
tive support from CORE. The donor prostatectomies har-
vested from brain dead, perfused donors and are bathed
in Ringer's Lactate solution and transported on wet ice.
These donor prostates are transported and handled with
the harvested "transplant" organs. This significantly
reduces transit time and minimizes the degradation of
RNA. The processing methodologies used consist of snap
freezing tissues in bulk, freezing in OCT and processing
the tissues for routine histology (paraffin embedded tis-
sues). For microarray analysis, the donor samples were
excised from the same zone as the tumor samples. The 60
tumor samples used in this study consisted of 2, 13, 27, 6
and 12 cases of primary prostatic adenocarcinoma of
Gleason grade 5, 6, 7, 8 and 9 respectively. There were 4,
20, 23 and 13 cases spanning the age groups 40–49, 50–
59, 60–69 and 70–79 respectively. Of the cases, 36 were
stage T3 or higher with 2, 22, 23, 11 and 2 cases of stage
T2a, T2b, T3a, T3b and 4 respectively. Of the donors, 11
are under and 7 are over the age of 40. Complementary
RNA (cRNA) were prepared and hybridized to Affymetrix
oligonucleotide arrays as previously described [34]. Log
transformed prostate tissue expression levels of a panel of
seven key enzymes involved in the LA and AA pathways
were compared between the donors and prostate cancer
patients using two sample t-test. Seven individual probe
sets were available for the ∆-5 Desaturase. The test was
done on the mean log expression levels of these 6 probe
sets. Descriptive summary statistics were presented for
each of the 7 genes within both, the donor and tumor
groups. Differences in gene expressions were evaluated
using both t-tests of log-transformed data and the Wil-
coxon rank-sum test. Log-transformations were utilized
since data were relatively skewed. Rank-sum tests, which
are the non-parametric analog to t-tests and based on the
ranks of the data were utilized to assure that any viola-
tions of the assumptions for the t-test did not critically
affect results particularly by multiple comparisons, as they
would remain unchanged even after using the conserva-
tive Bonferroni adjustment (which is comparing the P-Journal of Carcinogenesis 2006, 5:9 http://www.carcinogenesis.com/content/5/1/9
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value to 0.05 divided by the number of comparisons). We
examined the mRNA levels of seven key enzymes involved
in the LA and AA pathways in microdissected, 18 human
donor (normal) prostates compared to 60 prostate
tumors (Gleason grades 8–10) by Affymetrix oligonucle-
otide array (Table 1 - see Figure 2). Comparison of the
gene expressions using t-test after log transformation as
well as by rank-sum test suggests that the differences,
wherever observed, are statistically highly significant.
Only the log-transformed t-test results are reported in this
study since the rank-sum test gave the same results. The
results were not affected by multiple comparisons, as they
remain unchanged even after using the conservative Bon-
ferroni adjustment (which is comparing the P-value to
0.05 divided by the number of comparisons). However,
the analyses conducted in the present study do not evalu-
ate the prognostic ability of these genes, they merely eval-
uate whether they are differentially expressed. Our data on
donors spanned from ages 5 to 60 and all tumor patients
are older than 40. Therefore, in order to examine whether
or not the differential gene expression between donors
and patients is affected by age specific differences in their
prostates, we segmented the donors into different age
groups and compared only the 40 to 60 year old donors
with tumors of the same age group. Although the number
of cases in the study were small, the expression pattern
observed in this age matched analysis is identical (data
not shown) to that when all donors are included suggest-
ing that potential age related differences in donor pros-
tates do not contribute to the results of the donor versus
tumor analysis. This comparative (normal donor versus
prostate cancer) study showed that: 1) the level of 15-LO-
1 expression (the key enzyme in the LA pathway) is low (P
< 0.001), whereas the levels of delta-5 desaturase (P <
0.001, the key enzyme in the AA pathway), delta-6 desat-
urase (P = 0.001), elongase (P = 0.16) and 15-lipoxygen-
ase-2 (15-LO-2, P = 0.74) are higher in donor (normal)
prostates, and 2) However in PCa tissues, significantly
high levels of only 15-LO-1; whereas low levels of delta-6
desaturase, elongase, delta-5 desaturase and 15-LO-2
respectively, were observed. Although the cyclooxygenase
(COX)-1 and COX-2 mRNA levels were high in PCa, no
significant differences were observed when compared in
donor tissues. This study suggests that an increase in the
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n-6 to n-3 PUFA ratio in diet when the n-6 enzymes such
as 15-LO-1 and COX-2 are aberrantly expressed can pro-
mote PCa, and the need for designing promising early die-
tary intervention agents such as the omega-3 fatty acids as
substrate competitors of LA/AA, aimed primarily at high
15-LO-1 and COX-2 as the molecular targets (Figure 1).
Early introduction of "good" metabolites by dietary n-3
PUFA thereby reducing the "bad" metabolites of dietary n-
6 can slow down or even inhibit PCa development in
individuals with aberrant 15-LO-1 and COX-2 expres-
sions. Thus, by combining a reduction of dietary n-6 fat
with an intake of n-3 fatty acids would be more attainable
and particularly beneficial to the approximately 80 mil-
lion baby boomers that will begin turning 60 years of age
in 2 years [2], and those who follow.
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